Detail akcie Larimar Therap Rg online

Business Summary: Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Larimar Therapeutics Inc revenues was not reported. Net loss increased 99% to $103.2M. Higher net loss reflects Research and Development increase from $43.7M to $92.1M (expense), Other income, net decrease of 32% to $5.3M (income), General and administrative increase of 15% to $10.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.86 to -$1.50.